HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis - PharmaTimes Bimekizumab offers fresh option for patients with chronic conditions

#HSE #HealthServiceExecutive #Ireland #hidradenitissuppurativa #HS #axialspondyloarthritis #axSpA #Bimekizumab #BIMZELEX #NadegeFeeser #Immunology #UCB #chronicdiseases #BrianKirby #Dermatology #HSpatients #phase3studies #clinicaltrial #BEHEARD1 #BEHEARD2 #moderatetosevereHS
zurl.co/NrDNa

SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...

Bimekizumab shows long-term efficacy in hidradenitis suppurativa - PharmaTimes UCB's BIMZELX reveals promising two-year data at EHSF 2025

#Bimekizumab #hidradenitissuppurativa #dermatology #UCB #UCBPharma #BIMZELX #EHSF2025 #BEHEARDtrials #HiSCR75responders #interleukin17Ainhibitor #IL17Ainhibitor #interleukin17Finhibitor #IL17Finhibitor #EuropeanHidradenitisSuppurativaFoundation #HSpatients
pharmatimes.com/news/bimekiz...